IDrugs
2003-05-01
SPM-927 (Schwarz Pharma).
Collin A Hovinga
Index: IDrugs 6(5) , 479-85, (2003)
Full Text: HTML
Abstract
Schwarz Pharma, under license from Harris FRC, is developing SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain.
Related Compounds
Related Articles:
Molecule of the month. Lacosamide.
2004-12-01
[Drug News Perspect. 17(10) , 689, (2004)]
Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study.
2003-12-04
[Neurosci. Lett. 352(2) , 117-20, (2003)]